Investigating the effect of probiotic supplementation on Brucellosis

Investigating the effect of probiotic supplementation on clinical manifestations and laboratory findings and the treatment process of patients with Brucellosis: A triple-blind randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240130060856N1

Enrollment

100

Registered

2024-02-13

Start date

2024-02-20

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis. Brucellosis

Interventions

Intervention 1: Intervention group: Daily taking of one Lactocare probiotic capsule containing 10^9 CFU of bacteria for 60 days. Intervention 2: Control group: Daily taking of one placebo capsule cont

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with new onset Brucellosis

Exclusion criteria

Exclusion criteria: Presence of immunodeficiency in the patient Taking immunosuppressive drugs Presence of concomitant diseases such as tuberculosis, malignancy, liver cirrhosis and ESRD Current pregnancy Presence of focal, complicated or chronic forms of Brucellosis

Design outcomes

Primary

Measure	Time frame
Duration of fever. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of chills. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of musculoskeletal pain. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of anorexia. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of weakness. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of diarrhea. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of nausea. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of esophagitis. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Wright. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;Coombs Wright. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;ESR. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;CRP. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;2ME. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.	—

Measure

Time frame

Duration of fever. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of chills. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of musculoskeletal pain. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of anorexia. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of weakness. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of diarrhea. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of nausea. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Duration of esophagitis. Timepoint: Daily from the beginning of the intervention until the symptom disappears. Method of measurement: Patient checklist.;Wright. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;Coombs Wright. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;ESR. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;CRP. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.;2ME. Timepoint: At baseline and 60 days after the initiation of trial. Method of measurement: Laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Amirhossein Mousavi

Arak University of Medical Sciences

mosavia7777@gmail.com+98 86 3417 3502

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026